Format

Send to

Choose Destination
See comment in PubMed Commons below
Obstet Gynecol. 2011 Feb;117(2 Pt 1):287-92. doi: 10.1097/AOG.0b013e31820513d9.

Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption.

Author information

1
Division of Medical Screening & Special Testing, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA. jhaddow@ipmms.org

Abstract

OBJECTIVE:

To estimate the relationship between thyroid antibodies and placental abruption.

METHODS:

This cohort study assesses thyroperoxidase and thyroglobulin antibodies in relation to placental abruption among 10,062 women with singleton viable pregnancies (from the First and Second Trimester Risk of Aneuploidy [FaSTER] trial). A thyroperoxidase antibody cutoff of 50 international units/mL is used for comparison with published data from another cohort.

RESULTS:

Women with elevated thyroperoxidase antibody levels in the first and second trimesters have a higher rate of placental abruption than antibody-negative women. This relationship is less strong in the first trimester (1.51% compared with 0.83%; odds ratio [OR], 1.83; 95% confidence interval [CI], 0.99-3.37) than in the second trimester (1.78% compared with 0.82%; OR, 2.20; 95% CI, 1.21-3.99). A similar, but weaker, relationship is present for thyroglobulin antibodies. Sixty-four of 782 thyroperoxidase antibody-positive pregnancies without abruption become negative by the second trimester; one pregnancy with abruption becomes antibody-positive. Odds ratios for pregnancies with both thyroperoxidase and thyroglobulin antibody elevations are also higher (first trimester: OR, 2.10; 95% CI, 0.91-4.86; second trimester: OR, 2.73; 95% CI, 1.17-6.33).

CONCLUSION:

The present data confirm an association between thyroid antibody elevations and placental abruption described in a recent report. These findings, however, do not provide support for recommending routine testing for thyroid antibodies during pregnancy.

LEVEL OF EVIDENCE:

II.

PMID:
21252741
DOI:
10.1097/AOG.0b013e31820513d9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center